Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.36 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | LIPE | Q05469 | 3/20 | 0.32 |
| ▸ | GLS | O94925 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25252074 | 0.88 | LOXL2 (0.43) | LOXL2HCRTR2HCRTR1ABHD6FAAH | |
| SCHEMBL25298984 | 0.86 | GPR119 (0.48) | LOXL2GPR119DGAT1 | |
| SCHEMBL30395753 | 0.86 | GPR119 (0.48) | LOXL2GPR119DGAT1 | |
| SCHEMBL31307995 | 0.83 | HCRTR2 (0.35) | LOXL2HCRTR2HCRTR1 | |
| SCHEMBL25327189 | 0.81 | LOXL2 (0.34) | LOXL2HCRTR2HCRTR1ABHD6FAAH | |
| SCHEMBL30700149 | 0.81 | LOXL2 (0.36) | LOXL2HCRTR2HCRTR1ABHD6GPR119 | |
| SCHEMBL30553180 | 0.81 | LOXL2 (0.34) | LOXL2HCRTR2HCRTR1ABHD6FAAH | |
| SCHEMBL25411789 | 0.80 | GPR183 (0.37) | LOXL2ABHD6FAAHMGLLDGAT1 | |
| SCHEMBL25146053 | 0.80 | MGLL (0.43) | MGLL | |
| SCHEMBL25326016 | 0.80 | LOXL2 (0.33) | LOXL2HCRTR2HCRTR1ABHD6FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4208456-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | CBR3, BRIX1, CCNY | LOXL2 232/4885HCRTR2 867/4885HCRTR1 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.